학술논문
Incidence and clinical progression of placebo-treated amyloid-negative subjects with mild-to-moderate Alzheimer's disease (AD): Results from the phase III PET substudies of bapineuzumab and solanezumab
Document Type
Abstract
Author
Source
In Alzheimer's & Dementia: The Journal of the Alzheimer's Association July 2013 9(4) Supplement:P888-P889
Subject
Language
ISSN
1552-5260